On Demand: Tackling NF1-Associated Tumors with Targeted Therapy: A Clinical Update & Case-Based Challenges for the Neuro-Oncology Specialist

This educational activity is designed and developed to provide an interactive overview of novel and emerging data, as well as establish a foundational context of NF1 disease state complexity and intractability. This activity will begin by reviewing revised diagnostic criteria and hallmark aspects of NF1 natural history and clinical presentation in pediatric patients, and describing the genetic etiologies and multi-system pathophysiology that have historically made NF1-associated tumors so difficult to treat. Supported by a dynamic case-based approach intended to encourage audience interactivity, attendees will gain insights from renowned key opinion leaders regarding the pivotal shortcomings of traditional NF1 management modalities and the new horizons that have accompanied the emergence of targeted medical therapies, most notably MEK inhibitors. This discussion will be supported by a detailed appraisal of clinical trial data, treatment recommendations, and approved indications for targeted therapies in NF1. Finally, top-level neuro-oncology experts will guide attendees through a series of case-driven challenges meant to elucidate the role of the neuro-oncology specialist in the evolving NF1 tumor treatment calculus.


 

Target Audience

This educational initiative is targeted to neuro-oncologists, pediatric neurooncologists, neurosurgeons, neurologists, medical oncologists, and neuro-oncology researchers.This educational initiative is targeted to neuro-oncologists, pediatric neurooncologists, neurosurgeons, neurologists, medical oncologists, and neuro-oncology researchers.

Learning Objectives

  • Review recently-updated NF1 diagnostic criteria and recognize established NF1 clinical manifestations to promote earlier detection and treatment initiation, especially in pediatric patients.
  • Describe the genetic origin and complex pathophysiology of NF1, with a focus on the neuro-oncologic morbidity and historical intractability of symptomatic, inoperable plexiform neurofibromas.
  • Using an interactive, patient case-driven approach: Evaluate traditional NF1-associated plexiform neurofibroma treatment modalities, including surgery, radiation, and surveillance, and emphasize how targeted medical therapies are poised to revolutionize patient outcomes.
  • Appraise completed and ongoing clinical trial data for MEK inhibitors and other novel targeted therapies being studied in NF1-associated tumors, with an emphasis on current consensus recommendations and FDA-approved indications.
  • Evaluate traditional NF1-associated plexiform neurofibroma treatment modalities, including surgery, radiation, and surveillance, and emphasize how targeted medical therapies are poised to revolutionize patient outcomes. Discuss the essential placement of the neuro-oncology specialist on the multidisciplinary NF1 treatment team, and design practical, evidence-based treatment plans using targeted therapies for NF1-associated tumors.


Presented by Creative Educational Concepts, Inc (CEC Oncology).

Supported through an independent educational grant from AstraZeneca.

 

Additional Information

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
11/22/2021
Course expires: 
12/22/2021
Rating: 
0

5 min      Welcome and Introductions/Pre-test


15 min    The Fundamentals of Change: Genetic Etiology, Multisystem Pathophysiology, and Revised NF1 Diagnostic Criteria


25 min   A Paradigm Renewed: The Evidence Basis for Aiming Targeted Medical Therapies at NF1-Associated Tumors


35 min    Neuro-Oncology Notions: Real-World MEK Inhibitor Strategies for the Neuro-Oncologist in an Evolving Calculus


10 min    Conversations with the Experts: Audience Q&A/Post-test
 

Bruce R. Korf, MD, PhD
Associate Dean for Genomic Medicine, School of Medicine
Chief Genomics Officer, UAB Medicine
Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics
Professor of Genetics
Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine
The University of Alabama at Birmingham
Birmingham, AL

Dr. Bruce R. Korf is the Associate Dean for Genomic Medicine, School of Medicine; Chief Genomics Officer, UAB Medicine; Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics, Professor of Genetics, Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine, Associate Director for Rare Diseases, Hugh Kaul Personalized Medicine Institute and editor-in-chief of the American Journal of Human Genetics.  He is a medical geneticist, pediatrician, and child neurologist, certified by the American Board of Medical Genetics and Genomics (clinical genetics, clinical cytogenetics, and clinical molecular genetics), American Board of Pediatrics, and American Board of Psychiatry and Neurology (child neurology). Dr. Korf is past president of the Association of Professors of Human and Medical Genetics, past president of the American College of Medical Genetics and Genomics, and current president of the ACMG Foundation for Genetic and Genomic Medicine.  He has served on the Board of Scientific Counselors of the National Cancer Institute and the National Human Genome Research Institute at the NIH. His major research interests are molecular diagnosis of genetic disorders and the natural history, genetics, and treatment of neurofibromatosis.  He serves as principal investigator of the Department of Defense funded Neurofibromatosis Clinical Trials Consortium, the Alabama Genomic Health Initiative, and the Southern All of Us Network.  He is co-author of Human Genetics and Genomics (medical student textbook, now in fourth edition), Medical Genetics at a Glance (medical student textbook (now in third edition), Emery and Rimoin’s Principles and Practice of Medical Genetics (now in 6th edition), and Current Protocols in Human Genetics.

Justin Jordan, MD, MPH
Neuro-Oncologist
Clinical Director, MGH Pappas
Center for Neuro-Oncology
Director, Family Center for Neurofibromatosis
Massachusetts General Hospital
Boston, MA

Dr. Jordan is an assistant professor of neurology at Harvard Medical School and serves as the Director of the Family Center for Neurofibromatosis and as the Clinical Director for Neuro-Oncology at Massachusetts General Hospital. In addition to his clinical work, Dr. Jordan is involved in both translational and clinical research, including serving as site PI for the national Neurofibromatosis Clinical Trials Consortium. He is a leader in multiple national organizations, currently serving as a member of the Children’s Tumor Foundation Clinical Care Advisory Committee, vice chair of the Health Policy Subcommittee of American Academy of Neurology (AAN), member of the guidelines committee of the Society for Neuro-Oncology, and several other roles.

 


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Bruce R. Korf, MD, PhD– has disclosed he is a consultant for Genome Medical and SpringWorks Therapeutics. He has fiduciary responsibility with ACMG Foundation and receives grant/research support from AstraZeneca. 

Authors/Presenters:
Bruce R. Korf, MD, PhD– has disclosed he is a consultant for Genome Medical and SpringWorks Therapeutics. He has fiduciary responsibility with ACMG Foundation and receives grant/research support from AstraZeneca. 
Justin Jordan, MD, MPH– has disclosed he is a consultant for Navio Theragnostics and CereXis. 

Reviewer: Disclosure to come
 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 


Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Upon completion of a post-test and evaluation, statements of credit for physicians will be issued within 30 business days.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.